Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALDOSE-2 IMU-838 dose-finding trial in active Crohn's disease
NL-OMON48184Phase 2Recruiting
- Sponsor
- Immunic Therapeutics
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vidofludimus calcium in Crohn's disease (4 arms), sponsored by Immunic Therapeutics. Primary endpoint: Symptomatic remission at Week 14. Started Sep 2019; status: recruiting.
02
Drugs
vidofludimus calcium
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON48184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48184.